Biovica International
15.9.2021 08:21:46 CEST | ACCESS Newswire | Press release
UPPSALA, SE / ACCESSWIRE / September 15, 2021 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)
Biovica, active in cancer diagnostics, today announces that DiviTum®TKa results from an analysis of samples from the large SWOG S0226 study have been published in the highly ranked peer-reviewed scientific journal Clinical Cancer Research, published by the American Association for Cancer Research (AACR). The strong results support using DiviTum®TKa as a tool to monitor disease progression with endocrine therapy in women with hormone receptor positive metastatic breast cancer.
"SWOG researchers have demonstrated that a blood serum test can identify which of these patients have slow-growing disease that might be controlled with a simple aromatase inhibitor pill alone," said co-author of the paper, Dr. Lajos Pusztai, MD, PhD, Yale University Cancer Center.
"We are very proud to see the strong DiviTum®TKa results being published in Clinical Cancer Research. This highly reputable scientific journal by AACR focuses on innovative clinical and translational research bridging the laboratory and the clinic. The publication is a great recognition for DiviTumTKa and an important step to establishing the test as a standard tool for monitoring treatment of metastatic breast cancer to the benefit of patients and payers," said Anders Rylander, CEO of Biovica.
As previously announced, results demonstrate that patients with low TKa levels (using a predefined cut-off) before treatment initiation will do significantly better than patients expressing high levels of TKa. Progression free survival (PFS) was 17.3 vs 11.2 months and overall survival (OS) was 58 vs 30 months, respectively. In addition, similar results were observed during treatment, where patients with low TKa showed significantly longer PFS and OS. Furthermore, results support the potential clinical use of DiviTum®TKa to identify low-TKa patients as best suited for endocrine monotherapy, whereas those with elevated TKa values appear to benefit from combination therapies.
The analysis measured thymidine kinase activity (TKa) levels in 1,726 serum samples from more than 400 patients in SWOG S0226 and is the largest study to evaluate DiviTum®TKa for prognostic and serial monitoring of metastatic breast cancer. The study constitutes the foundation for the clinical validation of DiviTum®TKa in Biovica's 510(k)-application to the FDA. DiviTum®TKa is 510(k) pending. Not available for sale in the United States.
Link to study: Clinical Cancer Research
Contact
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se , +46 8 528 00 399. For more information please visit: www.biovica.com .
SOURCE: Biovica International
View source version on accesswire.com:
https://www.accesswire.com/664165/DiviTumRTKa-Results-from-SWOG-Study-Published-in-Clinical-Cancer-Research
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
IXOPAY Launches Payments Intelligence and IXONav, an AI Payments Assistant Built to Unlock Real-Time Insights Across the Payments Journey2.6.2026 06:00:00 CEST | Press release
Company's intelligence layer combines AI-driven analytics with anomaly detection to improve merchant payments optimization, performance and revenue outcomes LEHI, UT / ACCESS Newswire / June 2, 2026 / IXOPAY, the performance layer powering global payments for the agentic era, today announced IXOPAY Payments Intelligence, a unified control center that transforms fragmented payment data into real-time, actionable insights. The company also launched IXONav, a new AI agentic navigator built to unlock key insights at every step in the payments journey. By combining AI-driven analytics, anomaly detection and LLM agents, the platform helps merchants uncover optimization opportunities, improve routing performance, increase authorization rates and reduce per-transaction costs. IXOPAY's no-code payments platform unifies payment orchestration, tokenization, and intelligence, and provides merchants with a configurable infrastructure to optimize their payments performance. The IXOPAY Payments Intel
Clean Air Metals Files Audited Annual Financial Statements for the Year Ended January 31, 20262.6.2026 03:00:00 CEST | Press release
THUNDER BAY, ON / ACCESS Newswire / June 1, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSX.V:AIR)(FRA:CKU)(OTCQB:CLRMF) announces that it has filed its audited consolidated financial statements and management's discussion and analysis for the year ended January 31, 2026, available for viewing on www.sedarplus.ca. Financial Highlights Total assets as at January 31, 2026 of $36,226,670 Total cash as at January 31, 2026 of $1,133,766 Working capital deficiency as at January 31, 2026 of $2,281,241 Shareholder's equity as at January 31, 2026 of $32,604,804 During the year ended January 31, 2026, the Company incurred $1,190,489 in cost for exploration activities at the TBN project. Early in the year, the Company's management team executed a successful drill program at the Current Deposit to delineate larger ballroom structures. This was followed up by a significant undertaking at the Escape Deposit down plunge, to reassess past MT data and refine drilling targets in
Graid Technology Launches VROC(TM) by Graid Technology with 24-Month Roadmap and Tier 1 OEM Support2.6.2026 02:00:00 CEST | Press release
VROC™ by Graid Technology brings active development, Intel® Xeon® 6 platform support, and no-cost upgrades to an established CPU-based NVMe RAID foundation. SUNNYVALE, CA / ACCESS Newswire / June 1, 2026 / Graid Technology, creator of SupremeRAID™ and global steward of Intel® VROC, today announced VROC™ by Graid Technology, a rebranded and actively developed platform with a 24-month roadmap delivering new features, expanded platform support, and long-term investment for existing and future customers. Intel® VROC has served as the CPU-based software RAID foundation for Intel-powered enterprise servers across Tier 1 platforms worldwide. Under Graid Technology's stewardship, the product transitions from sustained maintenance into active development with no disruption to existing deployments. The VROC™ by Graid Technology roadmap includes: Intel® Xeon® 6 platform support - including Oak Stream (Diamond Rapids) - with no-cost upgrades for existing Intel® VROC customers Hardware key eliminat
Karbon-X to Present at the Small Cap Growth Virtual Investor Conference June 4th1.6.2026 15:30:00 CEST | Press release
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com CALGARY, AB / ACCESS Newswire / June 1, 2026 / Karbon-X Corp. (OTCQB:KARX), based in Calgary, Alberta focused on global carbon markets and climate infrastructure solutions, today announced that Chad Clovis, Chief Executive Officer will present live at the Small Cap Growth Virtual Investor Conference hosted by VirtualInvestorConferences.com, on June 4, 2026 DATE: June 4th TIME: 10:00 AM ET REGISTER HERE Available for 1x1 meetings: June 5th-9th Schedule 1x1 Meetings here. This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive
Resin Solutions LLC Introduces "Stratix(TM)" Brand Architecture for Products Serving the Aerospace and Defense Applications1.6.2026 15:00:00 CEST | Press release
EXTON, PA / ACCESS Newswire / June 1, 2026 / Resin Solutions LLC, a leading provider of advanced material solutions, today announced the launch of Stratix™, a new brand identity reflecting the company's deepened strategic focus on the Aerospace and Defense sector. This new designation underscores the company's long-term commitment to supporting the unique and demanding requirements of aerospace and defense customers. By clearly bringing both its existing and in-development aerospace and defense products under the Stratix™ brand name, Resin Solutions aims enhance customer confidence, streamline product selection, and further strengthen its partnerships within the sector. The Stratix™ brand trademark will be applied to a growing portfolio of materials engineered to meet the rigorous performance, quality, and reliability expectations critical to aerospace and defense applications. Among the first products to carry the designation are Resin Solutions' flagship and highly-specified aerospac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom